vTv Therapeutics begins randomisation in Phase 3 cadisegliatin trial for type 1 diabetes
Cadisegliatin, or TTP399, is a liver-selective glucokinase activator with FDA breakthrough therapy designation.
News
Genmab’s phase 3 trial of epcoritamab yields positive results in follicular lymphoma
XtalPi and DoveTree enter $6bn AI drug discovery partnership
Jazz secures FDA approval for Modeyso to treat rare brain tumour
SERB Pharma to acquire Y-mAbs Therapeutics for $412m
SOPHiA, AstraZeneca expand AI collaboration for breast cancer
Minaris Advanced Therapies opens new GMP facility in Germany
Turbine, Merck collaborate on cancer treatment development
